ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "HLA antigens"

  • 2018 American Transplant Congress

    Impact of Bw4 and Bw6 Epitope Mismatch on Clinical Outcomes after Renal Transplantation

    C. Liu,1 D. Brennan,2 K. Lentine,3 R. Delos Santos,1 J. Li,1 A. Malone,1 T. Alhamad.1

    1Washington University in St. Louis, St. Louis; 2Johns Hopkins University, Baltimore; 3Saint Louis University, St. Louis.

    HLA class II epitope mismatch has been shown to impact the long-term survival of kidney allografts. HLA-B alleles are traditionally grouped by the Bw4 and…
  • 2018 American Transplant Congress

    The Relative Immunogenicity of HLA Mismatches in Adult Liver Transplant Recipients

    V. Jucaud,1 A. Shaked,2 M. DesMarais,3 P. Sayre,3 M. Everly.1

    1Terasaki Research Institute, Los Angeles, CA; 2University of Pennsylvania, Philadelphia, PA; 3Immune Tolerance Network, Seattle, WA.

    Determining the immunogenicity of HLA mismatches (MM) may help preventing the appearance of de novo DSA (dnDSA) and avoiding antibody-mediated injuries.We studied the development of…
  • 2018 American Transplant Congress

    The Brazilian Epitope Virtual Crossmatch Protocol: A Reliable Tool for Increasing Kidney Allocation among Highly Sensitized Patients

    L. Sousa,1 A. Silva,1 M. Marroquim,1 A. Coelho,1 A. Lima,1 F. Silva,1 C. Carracosa,2 G. Willcox,3 T. Leão,3 B. Correa,3 E. Guimarães,3 G. Maciel,3 J. Andrade,4 A. Andrade,4 R. Neto,4 S. Cavalcante,4 C. Leão,4 F. Cavalcante,5 A. Holanda,5 N. Gomes,6 A. Rego,6 S. Monte.1

    1UFPI, Teresina, PI, Brazil; 2PUC, Curitiba, PR, Brazil; 3HLA Diagnostico, Recife, PE, Brazil; 4IMIP, Recife, PE, Brazil; 5RHP, Recife, PE, Brazil; 6CNCDO, Recife, PE, Brazil.

    Background: In Brazil (BZ), the kidney allocation policy for highly sensitized patients (HS) (PRA ≥ 80%) does not involve prioritization and transplants 10 times less…
  • 2018 American Transplant Congress

    Informatics Tools for Mapping Molecular HLA Typing Data to UNOS Antigen Equivalencies

    N. Kaur,1 E. Kransdorf,2 M. Pando,3 M. Maiers,4 L. Gragert.1,4

    1Tulane University School of Medicine, New Orleans; 2Cedars-Sinai Heart Institute, Los Angeles; 3Baylor Scott and White, Temple; 4National Marrow Donor Program / Be The Match, Minneapolis.

    Introduction:Molecular HLA typing must be converted to antigen equivalencies for entry into the UNOS database, UNet. Maintaining an up-to-date mapping table for this purpose has…
  • 2018 American Transplant Congress

    A Calculated Panel Reactive Antibody (CPRA) Calculator Supporting Both Allele-Level and Antigen-Level HLA Specificities

    L. Gragert,1,2 E. Kransdorf,3 N. Kaur,1 M. Maiers,2 J. Kobashigawa,3 M. Pando.4

    1Tulane University School of Medicine, New Orleans; 2National Marrow Donor Program / Be The Match, Minneapolis; 3Cedars-Sinai Heart Institute, Los Angeles; 4Baylor Scott and White, Temple.

    Introduction:The number of HLA alleles represented on Luminex assays has increased over time, allowing for improved characterization of anti-HLA antibody specificity. Calculated Panel Reactive Antibody…
  • 2018 American Transplant Congress

    Complement Activating HLA Class 2 Antibodies Are Associated with Poor Renal Allograft Survival; Multicentre Study

    A. Babu,1,2 O. Shaw,5 N. Khovanova,2 S. Griffin,4 D. Briggs,6 N. Krishnan,1 S. Fletcher,1 C. Imray,1 A. Seitz,3 R. Baker,3 M. Wellberry-Smith,3 B. Clarke,3 K. Cullen,3 F. Edwards,4 T. Rees,4 E. Burrows,4 L. Howe,5 R. Vaughan,5 N. Kessaris,7 N. Mamode,7 A. Dorling,7 D. Zehnder,1 R. Higgins,1,2 D. Mitchell,2 S. Daga.2,3

    1Renal Transplantation, University Hospitals Coventry, Coventry, United Kingdom; 2University of Warwick, Coventry, United Kingdom; 3Renal Transplantation, St James University Hospital, Leeds, United Kingdom; 4Renal Transplantation, University Hospital of Wales, Cardiff, United Kingdom; 5H&I, Viapath,, London, United Kingdom; 6H&I, NHSBT, Birmingham, United Kingdom; 7Renal Transplantation, Guys and St Thomas Hospital, London, United Kingdom.

    IntroductionRole of Class I and II pre-formed complement activating antibodies on renal outcomes is not well defined. In this multicentre study, we looked at the…
  • 2018 American Transplant Congress

    Determining the Relative Immunogenicity of HLA Mismatches with Calcineurin Inhibitor Immunosuppression: An Analysis of the BENEFIT and BENEFIT-EXT Renal Transplant Cohort

    V. Jucaud,1 M. Roberts,2 H. Gebel,3 R. Bray,3 M. Everly.1

    1Terasaki Research Institute, Los Angeles, CA; 2Immunology Biomarker Group, Bristol-Myers Squibb, Princeton, NJ; 3Pathology & Laboratory Medicine, Emory University School of Medicine, Atlanta, GA.

    We studied the relative immunogenicity of HLA-A, -B, -C, -DR and -DQ MM (serological) in a cohort of 291 kidney transplant patients from the BENEFIT…
  • 2018 American Transplant Congress

    High Frequency of HLA-DQ De Novo Donor Specific Antibodies is Independent of the Number of Mismatches in Heart Transplant

    X. Zhang,1 E. Kransdorf,2 J. Patel,2 J. Kobashigawa.2

    1HLA and Immunogenetics Laboratory/ Comprehensive Transplant Center, Cedars-Sinai Health Systems, Los Angeles, CA; 2Cardiology, Cedars-Sinai Medical Center, Los Angeles, CA.

    Aim: Development of de novo donor specific antibodies (DSA) after heart transplant is associated with an increased risk of allograft failure. The aim of this…
  • 2018 American Transplant Congress

    Not All HLA Mismatches Are Equal: Determining the Relative De Novo DSA Induction Capacity of HLA Mismatches

    V. Jucaud,1 L. Rebellato,2 K. Briley,2 A. Maldonado,3 C. Haisch,2 P. Bolin,2 S. Kendrick,4 H. Jones,4 K. McLawhorn,4 D. Leeser,2 M. Everly.1

    1Terasaki Research Institute, Los Angeles, CA; 2East Carolina University, Greenville, NC; 3Vidant Medical Center, Greenville, NC; 4Eastern Nephrology Associates, Greenville, NC.

    We studied the immunogenicity, defined as the development of de novo DSA (dnDSA), of HLA-A, -B, -DR and -DQ MM (serological) in a cohort of…
  • 2018 American Transplant Congress

    Peptides Encoded by EBV Latent Cycle Proteins Affect NK Cell Reactivity

    B. Mbiribindi, C. Romero Moreno, C. Esquivel, O. Martinez, S. Krams.

    Department of Surgery, Stanford University School of Medicine, Stanford, CA.

    Introduction: Epstein–Barr virus (EBV) infects more than 90% of adults worldwide and is associated with several malignancies, including post-transplant lymphoproliferative disorder (PTLD). Although EBV infection…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences